CoChat

Performance Assessment of Three Continuous Glucose Monitoring Systems in Adults With Type 1 Diabetes

Open access
Kölle, Julia, Eichenlaub, Manuel, Mende, Jochen, Link, Manuela, Vetter, Beatrice, Safary, Elvis, Pleus, Stefan, Haug, Cornelia, Freckmann, Guido · 2024 · Journal of Diabetes Science and Technology

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Abstract

Background: FIND, the global alliance for diagnostics, identified the nonmarket-approved continuous glucose monitoring (CGM) system, FiberSense system (FBS), as a potential device for use in low- and middle-income countries. Together with two market-approved, factory-calibrated CGM systems, namely, the FreeStyle Libre 2 (FL2) and the GlucoRx AiDEX (ADX), the FBS was subjected to a clinical performance evaluation. Methods: Thirty adult participants with type 1 diabetes were enrolled. The study was mainly conducted at home, with three in-clinic sessions conducted over the study period of 28 days. Comparator measurements were collected from capillary samples, using a high-quality blood glucose monitoring system. Results: Data from 31, 70, and 78 sensors of FBS, FL2, and ADX, respectively, were included in the performance analysis. The mean absolute relative differences between CGM and comparator data for FBS, FL2, and ADX were 14.7%, 9.2%, and 21.9%, and relative biases were −2.1%, −2.5%, and −18.5%, respectively. Analysis of individual sensor accuracy revealed low, moderate, and high sensor-to-sensor variability for FBS, FL2, and ADX, respectively. Sensor survival probabilities until the end of sensor life were 47.2% for FBS (28 days), 71.3% for FL2 (14 days), and 48.4% for ADX (14 days). Conclusions: The results of FBS were encouraging enough to conduct further performance and usability evaluations in a low- and middle-income country. The results of FL2 mainly agreed with existing studies, whereas ADX showed substantial deviations from previously reported results.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1177/19322968231159657

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. (a) Distribution of comparator blood glucose (BG) levels collected from all participants over the entire study period. (b) Distribution of comparator glucose rate of change (RoC) calculated for BG measurements spaced less than 20 minutes during frequent sampling periods on study days 2, 11, and 28.
Figure 1. (a) Distribution of comparator blood glucose (BG) levels collected from all participants over the entire study period. (b) Distribution of comparator glucose rate of change (RoC) calculated for BG measurements spaced less than 20 minutes during frequent sampling periods on study days 2, 11, and 28.CC BY-NC · PubMed Central
Figure 2. Results of the Continuous Glucose Deviation Interval and Variability Analysis (CG-DIVA). Absolute deviations are provided for comparator glucose levels <70 mg/dL and relative deviations for all other levels. Panels a-c show the deviation intervals as light/dark gray boxes, which indicate the range in which a certain share of deviations are expected to lie. These shares (printed above the plot) and the colored background were set according to the requirements defined by the U.S. Food and Drug Administration for “integrated” CGM systems. If the second deviation interval (light gray box) extends beyond the y-axis, its upper/lower limit is printed. The median deviations are shown by the black dashes. Panels d-f show the characterization of the sensor-to-sensor variability on a representative selection of 20 sensors. Each sensor is described by its median and 90%-range of deviations and sensors are ordered according to the median deviation in the total glucose range. If less than 10 data points within a range are available for a sensor, the full range of deviations is displayed and indicated with caps at the end of the antennae. Note that some antennae extend beyond the y-axis limits. Abbreviations: FBS, FiberSense CGM system; FL2, FreeStyle Libre 2 CGM system; ADX, GlucoRx AiDEX CGM system.
Figure 2. Results of the Continuous Glucose Deviation Interval and Variability Analysis (CG-DIVA). Absolute deviations are provided for comparator glucose levels <70 mg/dL and relative deviations for all other levels. Panels a-c show the deviation intervals as light/dark gray boxes, which indicate the range in which a certain share of deviations are expected to lie. These shares (printed above the plot) and the colored background were set according to the requirements defined by the U.S. Food and Drug Administration for “integrated” CGM systems. If the second deviation interval (light gray box) extends beyond the y-axis, its upper/lower limit is printed. The median deviations are shown by the black dashes. Panels d-f show the characterization of the sensor-to-sensor variability on a representative selection of 20 sensors. Each sensor is described by its median and 90%-range of deviations and sensors are ordered according to the median deviation in the total glucose range. If less than 10 data points within a range are available for a sensor, the full range of deviations is displayed and indicated with caps at the end of the antennae. Note that some antennae extend beyond the y-axis limits. Abbreviations: FBS, FiberSense CGM system; FL2, FreeStyle Libre 2 CGM system; ADX, GlucoRx AiDEX CGM system.CC BY-NC · PubMed Central
Figure 3. Sensor stability as characterized through mean absolute differences (MARD) on every study day including only sensors inserted on study day 1. The shaded areas indicate the 95% confidence intervals. The circled points indicate days that were at least partially spent at the study side; red circles indicate days with frequent sampling periods. Abbreviations: FBS, FiberSense CGM system; FL2, FreeStyle Libre 2 CGM system; ADX, GlucoRx AiDEX CGM system.
Figure 3. Sensor stability as characterized through mean absolute differences (MARD) on every study day including only sensors inserted on study day 1. The shaded areas indicate the 95% confidence intervals. The circled points indicate days that were at least partially spent at the study side; red circles indicate days with frequent sampling periods. Abbreviations: FBS, FiberSense CGM system; FL2, FreeStyle Libre 2 CGM system; ADX, GlucoRx AiDEX CGM system.CC BY-NC · PubMed Central
Figure 4. Results of the survival analysis. The shaded areas indicate the 95% confidence intervals. The vertical dashes indicate sensors that were removed from participants prior to the end of their lifetime for reasons not related to the device. Abbreviations: FBS, FiberSense CGM system; FL2, FreeStyle Libre 2 CGM system; ADX, GlucoRx AiDEX CGM system.
Figure 4. Results of the survival analysis. The shaded areas indicate the 95% confidence intervals. The vertical dashes indicate sensors that were removed from participants prior to the end of their lifetime for reasons not related to the device. Abbreviations: FBS, FiberSense CGM system; FL2, FreeStyle Libre 2 CGM system; ADX, GlucoRx AiDEX CGM system.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Research works printed but not linked: 1

  1. Clinical Laboratory Standards Institute. POCT05—Performance Metrics for Continuous Interstitial Glucose Monitoring. 2nd ed. Wayne, PA: Clinical and Laboratory Standards Institute; 2020.

Cited by

See all 10

Metadata

Authors
Kölle, J., Eichenlaub, M., Mende, J., Link, M., Vetter, B., Safary, E., Pleus, S., Haug, C., & Freckmann, G.
Affiliations
  • Universität Ulm (DE)
  • FIND (CH)
Corresponding author
Eichenlaub, Manuel
Venue
Journal of Diabetes Science and Technology
Published
2023-02-22
Volume
18
Issue
6
Pages
1424-1432
ISSN
1932-2968 (ISSN-L)
OpenAlex
W4321497539
Cited by
9
References
14
Citations by year
2026: 1 · 2025: 2 · 2024: 5 · 2023: 1
FWCI
1.83
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of Diabetes Science and Technology (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
FIND
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Physical Sciences › Chemistry › Analytical Chemistry › Electrochemical sensors and biosensors
  • Health Sciences › Health Professions › Medical Laboratory Technology › Clinical Laboratory Practices and Quality Control
Keywords
continuous glucose monitoring, type 1 diabetes, FreeStyle Libre 2, sensor accuracy, low- and middle-income countries, device performance evaluation
MeSH terms
Continuous Glucose Monitoring, Adult, Blood Glucose, Diabetes Mellitus, Type 1, Female, Humans, Male, Middle Aged, Blood Glucose Self-Monitoring, Reproducibility of Results, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Performance Assessment of Three Continuous Glucose Monitoring Systems in Adults With Type 1 Diabetes. https://app.cochat.ai/papers/10.1177/19322968231159657
The paper
Kölle, J., Eichenlaub, M., Mende, J., Link, M., Vetter, B., Safary, E., Pleus, S., Haug, C., & Freckmann, G. (2024). Performance Assessment of Three Continuous Glucose Monitoring Systems in Adults With Type 1 Diabetes. Journal of Diabetes Science and Technology. https://doi.org/10.1177/19322968231159657

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.